Abstract
Recent discoveries in the field of biomarkers for screening and early detection of ovarian cancer (OC) identified current needs for biomarkers capable of recognizing preclinical disease. The suggested approaches are (1) development of highly analytically sensitive CA 125 assays capable of detecting CA 125 released from small cancerous and preneoplastic lesions; (2) identification of biomarkers effective in CA 125-negative cases; and (3) performing biomarker discovery in samples obtained from patients with prophylactic bilateral salpingo-oophorectomy with pathologically confirmed preneoplastic lesions, or in appropriate animal models of ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
